FMDV and E2 fusion proteins and uses thereof
AssigneeBoehringer Ingelheim Animal Health USA Inc.
InventorsJean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
Life of this patent
Estimating the term…
Abstract
The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
Claims8
A method of vaccinating a host susceptible to ovine, bovine, caprine, or swine Foot-and-Mouth Disease Virus (FMDV), or protecting or preventing the host against FMDV infection, or eliciting a protective immune response in a host, comprising at least one administration of a composition or vaccine comprising an FMDV antigen or polypeptide;
- wherein the FMDV antigen or polypeptide has at least 90% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:2, 4, 6, 8, 10, 12 or 14.
A method of producing an antigen comprising the steps of:
- i) linking a polynucleotide encoding the antigen to a polynucleotide encoding an E2 protein;
- ii) expressing the fusion protein in a host;
- and iii) isolating the fusion protein from the host;
- wherein the polynucleotide has at least 70% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1, 3, 5, 7, 9, 11 or 13.
Dependencies are inferred from the claim text.